3-10289773-G-T

Variant summary

Our verdict is Benign. The variant received -13 ACMG points: 0P and 13B. BP4_StrongBP6BA1

The NM_016362.5(GHRL):​c.214C>A​(p.Leu72Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0819 in 1,601,724 control chromosomes in the GnomAD database, including 6,195 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.073 ( 565 hom., cov: 31)
Exomes 𝑓: 0.083 ( 5630 hom. )

Consequence

GHRL
NM_016362.5 missense

Scores

4
13

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1U:1B:4O:1

Conservation

PhyloP100: 2.30

Publications

190 publications found
Variant links:
Genes affected
GHRL (HGNC:18129): (ghrelin and obestatin prepropeptide) This gene encodes the ghrelin-obestatin preproprotein that is cleaved to yield two peptides, ghrelin and obestatin. Ghrelin is a powerful appetite stimulant and plays an important role in energy homeostasis. Its secretion is initiated when the stomach is empty, whereupon it binds to the growth hormone secretagogue receptor in the hypothalamus which results in the secretion of growth hormone (somatotropin). Ghrelin is thought to regulate multiple activities, including hunger, reward perception via the mesolimbic pathway, gastric acid secretion, gastrointestinal motility, and pancreatic glucose-stimulated insulin secretion. It was initially proposed that obestatin plays an opposing role to ghrelin by promoting satiety and thus decreasing food intake, but this action is still debated. Recent reports suggest multiple metabolic roles for obestatin, including regulating adipocyte function and glucose metabolism. Alternative splicing results in multiple transcript variants. In addition, antisense transcripts for this gene have been identified and may potentially regulate ghrelin-obestatin preproprotein expression. [provided by RefSeq, Nov 2014]
GHRLOS (HGNC:33885): (ghrelin opposite strand/antisense RNA) This gene is an antisense gene of the ghrelin/obestatin prepropeptide gene. Alternatively spliced transcript variants have been identified and they may function as non-coding regulatory RNAs. [provided by RefSeq, Jan 2013]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0015681088).
BP6
Variant 3-10289773-G-T is Benign according to our data. Variant chr3-10289773-G-T is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 5062.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.185 is higher than 0.05.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_016362.5. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
GHRL
NM_016362.5
MANE Select
c.214C>Ap.Leu72Met
missense
Exon 4 of 6NP_057446.1Q9UBU3-1
GHRL
NM_001302821.2
c.214C>Ap.Leu72Met
missense
Exon 5 of 7NP_001289750.1Q9UBU3-1
GHRL
NM_001302822.2
c.214C>Ap.Leu72Met
missense
Exon 4 of 6NP_001289751.1Q9UBU3-1

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
GHRL
ENST00000335542.13
TSL:1 MANE Select
c.214C>Ap.Leu72Met
missense
Exon 4 of 6ENSP00000335074.8Q9UBU3-1
GHRL
ENST00000429122.1
TSL:1
c.214C>Ap.Leu72Met
missense
Exon 4 of 6ENSP00000414819.1Q9UBU3-1
GHRL
ENST00000457360.5
TSL:1
c.214C>Ap.Leu72Met
missense
Exon 4 of 6ENSP00000391406.1Q9UBU3-1

Frequencies

GnomAD3 genomes
AF:
0.0728
AC:
11029
AN:
151572
Hom.:
565
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.0217
Gnomad AMI
AF:
0.0352
Gnomad AMR
AF:
0.0729
Gnomad ASJ
AF:
0.127
Gnomad EAS
AF:
0.195
Gnomad SAS
AF:
0.0910
Gnomad FIN
AF:
0.137
Gnomad MID
AF:
0.0886
Gnomad NFE
AF:
0.0811
Gnomad OTH
AF:
0.0707
GnomAD2 exomes
AF:
0.0877
AC:
22035
AN:
251348
AF XY:
0.0898
show subpopulations
Gnomad AFR exome
AF:
0.0183
Gnomad AMR exome
AF:
0.0478
Gnomad ASJ exome
AF:
0.126
Gnomad EAS exome
AF:
0.189
Gnomad FIN exome
AF:
0.131
Gnomad NFE exome
AF:
0.0807
Gnomad OTH exome
AF:
0.0888
GnomAD4 exome
AF:
0.0829
AC:
120137
AN:
1450032
Hom.:
5630
Cov.:
30
AF XY:
0.0834
AC XY:
60262
AN XY:
722218
show subpopulations
African (AFR)
AF:
0.0185
AC:
617
AN:
33296
American (AMR)
AF:
0.0506
AC:
2263
AN:
44710
Ashkenazi Jewish (ASJ)
AF:
0.127
AC:
3319
AN:
26058
East Asian (EAS)
AF:
0.193
AC:
7658
AN:
39630
South Asian (SAS)
AF:
0.0892
AC:
7673
AN:
86014
European-Finnish (FIN)
AF:
0.124
AC:
6606
AN:
53370
Middle Eastern (MID)
AF:
0.0611
AC:
351
AN:
5740
European-Non Finnish (NFE)
AF:
0.0785
AC:
86466
AN:
1101286
Other (OTH)
AF:
0.0865
AC:
5184
AN:
59928
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.466
Heterozygous variant carriers
0
4784
9567
14351
19134
23918
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
3274
6548
9822
13096
16370
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0727
AC:
11026
AN:
151692
Hom.:
565
Cov.:
31
AF XY:
0.0759
AC XY:
5630
AN XY:
74146
show subpopulations
African (AFR)
AF:
0.0217
AC:
898
AN:
41366
American (AMR)
AF:
0.0728
AC:
1109
AN:
15236
Ashkenazi Jewish (ASJ)
AF:
0.127
AC:
440
AN:
3466
East Asian (EAS)
AF:
0.195
AC:
1001
AN:
5132
South Asian (SAS)
AF:
0.0913
AC:
438
AN:
4796
European-Finnish (FIN)
AF:
0.137
AC:
1436
AN:
10512
Middle Eastern (MID)
AF:
0.0816
AC:
24
AN:
294
European-Non Finnish (NFE)
AF:
0.0810
AC:
5500
AN:
67882
Other (OTH)
AF:
0.0705
AC:
148
AN:
2100
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.498
Heterozygous variant carriers
0
481
962
1443
1924
2405
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
132
264
396
528
660
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0761
Hom.:
1197
Bravo
AF:
0.0637
TwinsUK
AF:
0.0833
AC:
309
ALSPAC
AF:
0.0807
AC:
311
ESP6500AA
AF:
0.0232
AC:
102
ESP6500EA
AF:
0.0771
AC:
663
ExAC
AF:
0.0856
AC:
10388
Asia WGS
AF:
0.121
AC:
422
AN:
3478
EpiCase
AF:
0.0780
EpiControl
AF:
0.0837

ClinVar

ClinVar submissions
Significance:Conflicting classifications of pathogenicity
Revision:criteria provided, conflicting classifications
View on ClinVar
Pathogenic
VUS
Benign
Condition
-
1
1
Inherited obesity (2)
-
-
2
not provided (2)
-
-
1
Obesity (1)
1
-
-
Obesity, age at onset of (1)
-
-
-
Metabolic syndrome, susceptibility to (1)

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.14
BayesDel_addAF
Benign
-0.48
T
BayesDel_noAF
Benign
-0.31
CADD
Benign
23
DANN
Uncertain
0.99
DEOGEN2
Benign
0.19
T
Eigen
Uncertain
0.39
Eigen_PC
Uncertain
0.26
FATHMM_MKL
Benign
0.74
D
LIST_S2
Benign
0.71
T
MetaRNN
Benign
0.0016
T
MetaSVM
Benign
-1.0
T
MutationAssessor
Uncertain
2.4
M
PhyloP100
2.3
PrimateAI
Benign
0.45
T
PROVEAN
Benign
-0.42
N
REVEL
Benign
0.12
Sift
Benign
0.11
T
Sift4G
Benign
0.19
T
Polyphen
1.0
D
Vest4
0.38
MPC
0.054
ClinPred
0.025
T
GERP RS
3.4
PromoterAI
-0.030
Neutral
Varity_R
0.10
gMVP
0.12
Mutation Taster
=88/12
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs696217; hg19: chr3-10331457; COSMIC: COSV55056089; COSMIC: COSV55056089; API
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.